Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

European Commission Approves Frontline Luspatercept for Transfusion-Dependent Anemia in Lower-Risk MDS

April 3rd 2024

The European Commission has expanded its approval of luspatercept to include frontline treatment of transfusion-dependent anemia due to lower-risk MDS.

Selection and Sequencing of JAK Inhibitors for Patients With MF

April 3rd 2024

Raajit K. Rampal, MD, PhD, discusses choosing among JAK inhibitors based on specific patient needs, such as platelet counts and anemia, emphasizing the importance of using the full dose for best efficacy and how different scenarios might influence the choice and sequencing of these drugs in practice.

The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

April 3rd 2024

Andrew Kuykendall, MD, discusses the efficacy and adverse effects of fedratinib, highlighting its potential in the second-line setting for patients resistant to ruxolitinib, with updates from FREEDOM-2 emphasizing manageable gastrointestinal tolerability concerns.

Retrospective Study Shows HSCT Consolidation After Blast Reduction Improves OS in Chronic Phase–Reverted MPN

March 27th 2024

Patients with myeloproliferative neoplasms in accelerated or blast phase experience improved survival outcomes after hematopoietic cell transplantation.

Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

March 27th 2024

Drs Rampal and Kuykendall highlight the benefits of pacritinib for patients with low platelet counts, as evidenced by the PERSIST-2 study, and momelotinib for patients with anemia, as shown in the MOMENTUM Phase 3 Study, focusing on their efficacy in spleen volume reduction and symptom relief in patients with myelofibrosis.

Future Directions in Combination Therapies for Myelofibrosis

March 27th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, reflect on the future of combination therapies in treating myelofibrosis, emphasizing the need to align study endpoints with treatment goals and highlighting the potential of various combinations based on promising preclinical and early phase study results.

Luspatercept Provides Effective First-Line Alternative to ESAs in Lower-Risk MDS

March 26th 2024

Sunil Iyer, MD, expands on the impact of the FDA’s approval of luspatercept on the management of lower-risk myelodysplastic syndrome.

Momelotinib Efficacy Propels the Future Development of JAK Inhibitors in Myelofibrosis

March 25th 2024

Joseph G. Jurcic, MD, highlights findings from the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials in myelofibrosis.

Next-Generation JAK Inhibitors Signal the Future of Myelofibrosis Treatment Advances

March 22nd 2024

Joseph G. Jurcic, MD, discusses the benefits and limitations of several JAK inhibitors for patients with myelofibrosis.

Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001

March 20th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss luspatercept with or without ruxolitinib for the treatment of anemia in patients with myelofibrosis. The combination has demonstrated promise in reducing transfusion dependency, as seen in data from ACE-536-MF-001, with ongoing phase 3 trials.

Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034

March 20th 2024

Andrew Kuykendall, MD, highlights the potential of selinexor plus ruxolitinib in JAK inhibitor-naïve patients with MF based on promising response rates in XPORT-MF-034 updated results, with plans for a phase 3 study. He also noted the need to manage nausea as a adverse effect.

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in February 2024.

FDA ODAC Committee Votes In Favor of Benefit-Risk Profile of Imetelstat in Lower-Risk MDS

March 14th 2024

The FDA’s Oncologic Drugs Advisory Committee voted in favor of imetelstat for select patients with lower-risk myelodysplastic syndrome.

Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

March 13th 2024

Raajit K. Rampal, MD, PhD, discusses promising data on navtemadlin plus ruxolitinib for patients with myelofibrosis who had suboptimal responses to ruxolitinib, showing significant improvements in spleen and symptom responses, with further phase 3 studies anticipated.

Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

March 13th 2024

Andrew Kuykendall, MD, reviews data from TRANSFORM-1 on navitoclax plus ruxolitinib for untreated myelofibrosis, highlighting consistent response rates, no significant symptom improvement with the combination, and challenges managing thrombocytopenia caused by navitoclax, despite its activity and potential as a second-line treatment option.

Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2

March 6th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss how the combination of the BET inhibitor pelabresib and the JAK inhibitor ruxolitinib led to greater reductions in spleen size and symptoms compared to ruxolitinib alone in JAK inhibitor-naïve patients with intermediate- or high-risk myelofibrosis in the MANIFEST and MANIFEST-2 trials, with an acceptable safety profile, providing evidence that targeting multiple inflammatory pathways could lead to better disease control.

How JAK Inhibitors Have Shaped the Landscape of MF

March 6th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss how JAK inhibitors have reduced spleen size (splenomegaly) and constitutional symptoms like fatigue and fever in patients with myelofibrosis but that there is still room for improvement in treating other aspects of the disease like anemia and bone marrow fibrosis. They also share insights about the potential for combination therapies that target multiple pathways.

NCCN Lists Ropeginterferon Alfa-2B As Preferred First-Line Cytoreductive Therapy for Polycythemia Vera

February 28th 2024

The National Comprehensive Cancer Network recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.

Rusfertide More Than Triples Responses Vs Placebo in Phlebotomy-Dependent Polycythemia Vera

February 27th 2024

Rusfertide displayed activity in phlebotomy-dependent polycythemia vera.

Bezuclastinib Improves Mast Cell Burden, TSS Vs Placebo in Nonadvanced Systemic Mastocytosis

February 27th 2024

Bezuclastinib plus BSC improved mast cell burden and total symptom score vs placebo plus BSC in adult patients with nonadvanced systemic mastocytosis.